Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Healthcare Biotechnology
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on... see more

CSE:QNTM - Post Discussion

Quantum BioPharma Ltd > FSD Pharma Info
View:
Post by DavidRosenberg on Nov 02, 2021 1:01pm

FSD Pharma Info

Armed with a strong balance sheet, solid pipeline, and renowned clinical team, FSD intends to advance its lead drug candidates through clinical trials with the goal of providing therapies to the millions suffering from neurodegenerative and neuropsychiatric conditions.

Additional FSD Highlights

  • A strong balance sheet represented by no debt and over USD$43.2 million in cash as of June 30, 2021.
  • Today there is no cure for Multiple Sclerosis (MS). FSD Pharma will attempt to change that for millions of suffering people. FSD’s proprietary compound Lucid-MS has shown promising results to reverse progressive MS, in several animal models
  • Well-positioned to advance current pipeline and aggressively pursue additional acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on “Total Brain Health”.
  • Renowned clinical team led by Dr. Lakshmi P. Kotra, Senior Scientist at Krembil Brain Institute, University Health Network (UHN), and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra serves as CEO of FSD Pharma’s wholly-owned subsidiary, Lucid Psycheceuticals.

With experienced leadership, a diverse pipeline of clinical assets accompanied by exclusive licensing rights, and therapies advancing to treat pervasive medical conditions, like inflammation, MS and Depression, FSD Pharma is on a strong trajectory for growth.

Relevant articles/videos:

FSD Pharma ‘excited’ to acquire pharma group Lucid Psycheceuticals to complement existing efforts

FSD Pharma to continue opportunistic acquisitions in endocannabinoid and psychedelic segments – executive

FSD Pharma, Developing Treatments for Mental Health Disorders

Comment by JAKPUG4LIFE on Nov 02, 2021 1:08pm
Yet on the biggest facility, yet on cannabis, yet on biotech, yet on pea, yet on shareholder value, yet on all failed loi's, yet on an AD apology for lies and misdirection' yet on you stfu. Stay in your facebook group where only you and your few minions post the same dribble
Quantum BioPharma Ltd